HK1158520A1 - Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3- yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof - Google Patents
Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3- yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereofInfo
- Publication number
- HK1158520A1 HK1158520A1 HK11113010.6A HK11113010A HK1158520A1 HK 1158520 A1 HK1158520 A1 HK 1158520A1 HK 11113010 A HK11113010 A HK 11113010A HK 1158520 A1 HK1158520 A1 HK 1158520A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- quinuclidin
- carboxamide
- thiophene
- benzo
- chloro
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title 1
- SSRDSYXGYPJKRR-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-1-benzothiophene-2-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC(C=CC=C2Cl)=C2S1 SSRDSYXGYPJKRR-ZDUSSCGKSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11610608P | 2008-11-19 | 2008-11-19 | |
PCT/US2009/065173 WO2010059844A1 (en) | 2008-11-19 | 2009-11-19 | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1158520A1 true HK1158520A1 (en) | 2012-07-20 |
Family
ID=41786120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11113010.6A HK1158520A1 (en) | 2008-11-19 | 2011-11-30 | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3- yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
Country Status (35)
Country | Link |
---|---|
US (6) | US8642638B2 (ja) |
EP (4) | EP2889033B1 (ja) |
JP (6) | JP5272080B2 (ja) |
KR (3) | KR20110091549A (ja) |
CN (3) | CN102281878A (ja) |
AU (1) | AU2009316557B2 (ja) |
BR (1) | BRPI0922057A2 (ja) |
CA (3) | CA2744278C (ja) |
CL (3) | CL2011001178A1 (ja) |
CO (1) | CO6400190A2 (ja) |
CR (1) | CR20110267A (ja) |
CY (3) | CY1113671T1 (ja) |
DK (3) | DK2355822T3 (ja) |
EC (1) | ECSP11011076A (ja) |
ES (3) | ES2396300T3 (ja) |
HK (1) | HK1158520A1 (ja) |
HR (3) | HRP20130007T1 (ja) |
HU (2) | HUE037938T2 (ja) |
IL (5) | IL212921A (ja) |
LT (1) | LT2889033T (ja) |
MX (1) | MX2011005270A (ja) |
MY (2) | MY173229A (ja) |
NZ (2) | NZ613291A (ja) |
PE (1) | PE20110711A1 (ja) |
PH (2) | PH12014501629B1 (ja) |
PL (3) | PL2540297T3 (ja) |
PT (3) | PT2889033T (ja) |
RS (1) | RS52583B (ja) |
RU (3) | RU2532327C2 (ja) |
SG (1) | SG10201504102QA (ja) |
SI (3) | SI2889033T1 (ja) |
SM (2) | SMT201300003B (ja) |
TR (1) | TR201807944T4 (ja) |
WO (1) | WO2010059844A1 (ja) |
ZA (1) | ZA201104044B (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
EP2889033B1 (en) | 2008-11-19 | 2018-03-21 | Forum Pharmaceuticals Inc. | Treatment of negative symptoms of schizophrenia with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
NO3029039T3 (ja) | 2010-05-17 | 2018-01-20 | ||
EP2640378A4 (en) * | 2010-11-18 | 2014-05-21 | Envivo Pharmaceuticals Inc | INFLAMMATION TREATMENT WITH CERTAIN NICOTINIC ACID ALPHA-7 RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS |
US20140155429A1 (en) * | 2011-05-09 | 2014-06-05 | Envivo Pharmaceuticals, Inc. | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Nicotine |
AU2012279298A1 (en) * | 2011-07-01 | 2014-01-23 | Envivo Pharmaceuticals, Inc. | Methods of treatment of Limited Cognitive Impairment |
US9585877B2 (en) * | 2012-05-08 | 2017-03-07 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
EP3585400B1 (en) | 2017-02-27 | 2024-11-06 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Anti-psychotic composition and treatment methods |
EP3684463A4 (en) | 2017-09-19 | 2021-06-23 | Neuroenhancement Lab, LLC | NEURO-ACTIVATION PROCESS AND APPARATUS |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
WO2019133997A1 (en) | 2017-12-31 | 2019-07-04 | Neuroenhancement Lab, LLC | System and method for neuroenhancement to enhance emotional response |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
US11452839B2 (en) | 2018-09-14 | 2022-09-27 | Neuroenhancement Lab, LLC | System and method of improving sleep |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5122528A (en) | 1983-12-22 | 1992-06-16 | Erbamont, Inc. | Analgesic use of benzobicyclic carboxamides |
US4605652A (en) | 1985-02-04 | 1986-08-12 | A. H. Robins Company, Inc. | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes |
EP0385517B1 (en) | 1985-03-14 | 1993-04-14 | BEECHAM GROUP plc | Medicaments for the treatment of emesis |
HU202108B (en) | 1986-07-30 | 1991-02-28 | Sandoz Ag | Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol |
DE3827253A1 (de) | 1987-08-20 | 1989-03-02 | Sandoz Ag | Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen |
DE3740984A1 (de) | 1987-12-03 | 1989-06-15 | Sandoz Ag | N-oxide von heterocyclischen carbonsaeurederivaten bzw. verfahren zu deren herstellung und deren verwendung |
IL88615A (en) | 1987-12-10 | 1992-11-15 | Duphar Int Res | 1,7-annelated indolecarboxylic acid esters and carboxamides,their preparation and pharmaceutical compositions containing them |
US5198437A (en) | 1987-12-10 | 1993-03-30 | Duphar International Research B.V. | 1,7-annelated indolecarboxylic acid esters and amides |
US4863919A (en) | 1988-02-01 | 1989-09-05 | A. H. Robins Company, Incorporated | Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes |
DE3810552A1 (de) | 1988-03-29 | 1989-10-19 | Sandoz Ag | Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben |
EP0353371A1 (en) | 1988-08-04 | 1990-02-07 | Synthelabo | Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides |
IE62662B1 (en) | 1989-01-06 | 1995-02-22 | Elan Corp Plc | Use of nicotine in the treatment of conditions susceptible to said treatment |
US5189041A (en) | 1990-11-16 | 1993-02-23 | Syntex (U.S.A.) Inc. | Tricyclic 5-ht3 receptor antagonists |
US5114947A (en) | 1990-12-27 | 1992-05-19 | Erbamont Inc. | Method for alleviating anxiety using benzobicyclic carboxamides |
DE4115215A1 (de) | 1991-05-10 | 1992-11-12 | Merck Patent Gmbh | Indolderivate |
SE9201478D0 (sv) | 1992-05-11 | 1992-05-11 | Kabi Pharmacia Ab | Heteroaromatic quinuclidinenes, their use and preparation |
US5977144A (en) | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
KR100366331B1 (ko) | 1994-08-24 | 2003-04-10 | 아스트라제네카 악티에볼라그 | 치료에유용한스피로-아자비시클릭화합물 |
US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
US5703116A (en) | 1995-04-18 | 1997-12-30 | Geron Corporation | Telomerase Inhibitors |
US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
GB9606736D0 (en) | 1996-02-19 | 1996-06-05 | Shire International Licensing | Therapeutic method |
FR2756826B1 (fr) | 1996-12-05 | 1999-01-08 | Adir | Nouveaux derives tetrahydropyridiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CN1157392C (zh) | 1997-05-30 | 2004-07-14 | 神经研究公司 | 在尼古丁ach受体上作为胆碱能配体的8-氮杂双环(3,2,1)辛-2-烯以及辛烷衍生物 |
US7214686B2 (en) | 1997-06-30 | 2007-05-08 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
JPH1180027A (ja) | 1997-09-12 | 1999-03-23 | Dai Ichi Seiyaku Co Ltd | 向知性薬 |
US6875606B1 (en) | 1997-10-23 | 2005-04-05 | The United States Of America As Represented By The Department Of Veterans Affairs | Human α-7 nicotinic receptor promoter |
US6277870B1 (en) | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
AU6394399A (en) | 1998-09-18 | 2000-04-10 | Rockefeller University, The | Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses thereof |
US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
US6432975B1 (en) | 1998-12-11 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
SE9900100D0 (sv) | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
FR2790474B1 (fr) | 1999-03-05 | 2001-04-06 | Synthelabo | Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique |
FR2791678B1 (fr) | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique |
US6416735B1 (en) | 1999-11-08 | 2002-07-09 | Research Triangle Institute | Ligands for α-7 nicotinic acetylcholine receptors based on methyllcaconitine |
CA2393004A1 (en) | 1999-12-01 | 2001-06-07 | Ortho-Mcneil Pharmaceutical, Inc. | Method of diagnosing neurodegenerative disease |
CA2393538A1 (en) | 1999-12-14 | 2001-06-21 | Pharmacia & Upjohn Company | Human ion channels |
FR2804430B1 (fr) | 2000-01-28 | 2002-03-22 | Sanofi Synthelabo | Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique |
GB0010955D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
DE60106022T2 (de) | 2000-06-06 | 2006-03-09 | Pfizer Products Inc., Groton | Thiophenverbindungen zur verwendung als antikrebsmittel |
TW593223B (en) | 2000-06-20 | 2004-06-21 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists |
FR2810664B1 (fr) | 2000-06-27 | 2004-12-24 | Adir | Nouveaux composes cyclopropaniques 1,1 et 1,2-dissubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP4616971B2 (ja) | 2000-07-18 | 2011-01-19 | 田辺三菱製薬株式会社 | 1−アザビシクロアルカン化合物およびその医薬用途 |
US20030092613A1 (en) | 2000-08-14 | 2003-05-15 | Lee Daniel H. S. | Alpha7 nicotinic receptor peptides as ligands for beta amyloid peptides |
US6492386B2 (en) | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
US6492385B2 (en) | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
WO2002016358A2 (en) | 2000-08-18 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
AU2001282875A1 (en) | 2000-08-21 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
DE10044905A1 (de) | 2000-09-12 | 2002-03-21 | Merck Patent Gmbh | (2-Azabicyclo[2.2.1]hept-7-yl)methanol-Derivate als nikontinische Acetylcholinrezeptor Agonisten |
US20020086871A1 (en) | 2000-12-29 | 2002-07-04 | O'neill Brian Thomas | Pharmaceutical composition for the treatment of CNS and other disorders |
EP1231212B1 (en) | 2001-02-06 | 2006-12-20 | Pfizer Products Inc. | Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders |
GB0108337D0 (en) | 2001-04-03 | 2001-05-23 | Novartis Ag | Organic compounds |
US6569865B2 (en) | 2001-06-01 | 2003-05-27 | Astrazeneca Ab | Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine |
AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
CA2455773A1 (en) | 2001-08-24 | 2003-03-06 | Pharmacia & Upjohn Company | Substituted-aryl 7-aza¬2.2.1|bicycloheptanes for the treatment of disease |
JP2003081978A (ja) | 2001-09-10 | 2003-03-19 | Mitsubishi Pharma Corp | スピロ環式化合物およびその医薬用途 |
CA2460075A1 (en) | 2001-09-12 | 2003-03-20 | Donn Gregory Wishka | Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases |
PL369895A1 (en) | 2001-10-02 | 2005-05-02 | Pharmacia & Upjohn Company | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
EP1438308A1 (en) | 2001-10-26 | 2004-07-21 | PHARMACIA & UPJOHN COMPANY | N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists |
MXPA04004464A (es) | 2001-11-08 | 2004-08-11 | Upjohn Co | Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades. |
GB0127008D0 (en) | 2001-11-09 | 2002-01-02 | Novartis Ag | Organic compounds |
WO2003042210A1 (en) | 2001-11-09 | 2003-05-22 | Pharmacia & Upjohn Company | Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands |
DE10156719A1 (de) | 2001-11-19 | 2003-05-28 | Bayer Ag | Heteroarylcarbonsäureamide |
FR2832714B1 (fr) | 2001-11-23 | 2004-07-16 | Sanofi Synthelabo | Derives de 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique |
FR2832713B1 (fr) | 2001-11-23 | 2004-02-13 | Sanofi Synthelabo | Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique |
FR2832712B1 (fr) | 2001-11-23 | 2004-02-13 | Sanofi Synthelabo | Derives de 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique |
CN100371714C (zh) | 2001-12-14 | 2008-02-27 | 塔加西普特公司 | 治疗中枢神经系统病症的方法和组合物 |
DE10162442A1 (de) | 2001-12-19 | 2003-07-03 | Bayer Ag | Monocyclische N-Aryl-amide |
DE10162375A1 (de) | 2001-12-19 | 2003-07-10 | Bayer Ag | Bicyclische N-Aryl-amide |
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
US6852716B2 (en) | 2002-02-15 | 2005-02-08 | Pfizer Inc | Substituted-aryl compounds for treatment of disease |
EP1476449A1 (en) | 2002-02-19 | 2004-11-17 | PHARMACIA & UPJOHN COMPANY | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
JP2005523287A (ja) | 2002-02-19 | 2005-08-04 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 疾患治療用アザビシクロ化合物 |
BR0307874A (pt) | 2002-02-20 | 2004-12-28 | Upjohn Co | Atividade de compostos azabicìclicos com receptor de acetilcolina nicotìnica alfa7 |
DE10211415A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
DE10211416A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Essig- und Propionsäureamide |
US20030236287A1 (en) | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
CA2487236A1 (en) | 2002-05-09 | 2003-11-20 | Memory Pharmaceuticals Corporation | Qm-7 and qt-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells |
EP1530467A2 (en) | 2002-07-17 | 2005-05-18 | Warner-Lambert Company LLC | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
DE10234424A1 (de) | 2002-07-29 | 2004-02-12 | Bayer Ag | Benzothiophen-, Benzofuran- und Indolharnstoffe |
WO2004014909A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
AU2003249532A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors |
GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
SK288115B6 (sk) | 2002-09-25 | 2013-09-03 | Memory Pharmaceuticals Corporation | Indazoles, pharmaceutical compositions comprising them and their use |
CN1726033A (zh) | 2002-12-11 | 2006-01-25 | 法马西亚和厄普乔恩公司 | 用α7烟碱乙酰胆碱受体激动剂和其它化合物的联合治疗疾病 |
US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
BRPI0408815A (pt) | 2003-03-28 | 2006-04-04 | Pharmacia & Upjohn Co Llc | moduladores alostéricos positivos do receptor nicotìnico da acetilcolina |
US20050119249A1 (en) | 2003-12-02 | 2005-06-02 | Erik Buntinx | Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
US20050245531A1 (en) | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
EP2336128A1 (en) | 2004-03-25 | 2011-06-22 | Memory Pharmaceuticals Corporation | Benzoisothiazoles and preparation and uses thereof |
AU2004325725A1 (en) | 2004-12-10 | 2006-06-22 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
WO2007038367A1 (en) | 2005-09-23 | 2007-04-05 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
WO2008051547A1 (en) | 2006-10-23 | 2008-05-02 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
SI2152712T1 (sl) | 2007-05-11 | 2012-03-30 | Pfizer | Amino heterociklične spojine |
US7935815B2 (en) | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
CN101815713B (zh) | 2007-08-31 | 2013-09-11 | 卫材R&D管理有限公司 | 多环化合物 |
MX2010003375A (es) | 2007-10-01 | 2010-05-17 | Comentis Inc | Derivados de 1h-indol-3-carboxilato de quinuclidin-4-ilmetilo como ligandos del receptor de acetilcolina alfa 7 nicotinico para el tratamiento de enfermedad de alzheimer. |
AU2008326360A1 (en) | 2007-11-21 | 2009-05-28 | Abbott Laboratories | Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators |
AU2009242127B2 (en) | 2008-04-29 | 2014-03-27 | Pharnext | New therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of cell stress response |
NZ589304A (en) | 2008-04-29 | 2012-03-30 | Pharnext | Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
LT2282778T (lt) | 2008-04-29 | 2017-06-26 | Pharnext | Nauji terapijos būdai, gydant alzheimerio ligą ir susijusius sutrikimus per angiogenezės moduliaciją |
JP2012508768A (ja) | 2008-11-13 | 2012-04-12 | リンク・メディスン・コーポレーション | アザキノリノン誘導体及びその使用 |
EP2889033B1 (en) | 2008-11-19 | 2018-03-21 | Forum Pharmaceuticals Inc. | Treatment of negative symptoms of schizophrenia with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
WO2010071846A2 (en) | 2008-12-19 | 2010-06-24 | Afraxis, Inc. | Compounds for treating neuropsychiatric conditions |
WO2010075635A1 (en) | 2008-12-30 | 2010-07-08 | Ramot At Tel Aviv University Ltd. | Combination therapies using nap |
TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基-雜環化合物 |
EP2398500B1 (en) | 2009-02-20 | 2019-03-13 | 2-BBB Medicines B.V. | Glutathione-based drug delivery system |
SG173710A1 (en) | 2009-02-26 | 2011-09-29 | Eisai R&D Man Co Ltd | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors |
PT2419104T (pt) | 2009-04-13 | 2018-01-31 | Theravance Biopharma R&D Ip Llc | Combinações de agonistas do recetor 5-ht4 e inibidores da acetilcolinesterase para o tratamento de distúrbios cognitivos |
MX2011013016A (es) | 2009-06-05 | 2012-04-20 | Link Medicine Corp | Derivados de aminopirrolidinona y usos de los mismos. |
US20110262442A1 (en) | 2009-11-06 | 2011-10-27 | Adenios, Inc. | Compositions for treating cns disorders |
US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
-
2009
- 2009-11-19 EP EP15151165.6A patent/EP2889033B1/en active Active
- 2009-11-19 EP EP18152484.4A patent/EP3357495B1/en active Active
- 2009-11-19 US US13/129,782 patent/US8642638B2/en not_active Expired - Fee Related
- 2009-11-19 DK DK09756921.4T patent/DK2355822T3/da active
- 2009-11-19 NZ NZ613291A patent/NZ613291A/en not_active IP Right Cessation
- 2009-11-19 PL PL12185913T patent/PL2540297T3/pl unknown
- 2009-11-19 KR KR1020117013996A patent/KR20110091549A/ko not_active Application Discontinuation
- 2009-11-19 PT PT151511656T patent/PT2889033T/pt unknown
- 2009-11-19 SG SG10201504102QA patent/SG10201504102QA/en unknown
- 2009-11-19 CA CA2744278A patent/CA2744278C/en not_active Expired - Fee Related
- 2009-11-19 EP EP12185913.6A patent/EP2540297B1/en active Active
- 2009-11-19 PL PL09756921T patent/PL2355822T3/pl unknown
- 2009-11-19 PL PL15151165T patent/PL2889033T3/pl unknown
- 2009-11-19 MX MX2011005270A patent/MX2011005270A/es active IP Right Grant
- 2009-11-19 CN CN2009801546937A patent/CN102281878A/zh active Pending
- 2009-11-19 CN CN201610021941.2A patent/CN105687191A/zh active Pending
- 2009-11-19 KR KR1020147032489A patent/KR20140146216A/ko not_active Application Discontinuation
- 2009-11-19 SI SI200931855T patent/SI2889033T1/en unknown
- 2009-11-19 AU AU2009316557A patent/AU2009316557B2/en not_active Ceased
- 2009-11-19 LT LTEP15151165.6T patent/LT2889033T/lt unknown
- 2009-11-19 KR KR1020187002503A patent/KR20180011888A/ko not_active Application Discontinuation
- 2009-11-19 RS RS20120560A patent/RS52583B/en unknown
- 2009-11-19 ES ES09756921T patent/ES2396300T3/es active Active
- 2009-11-19 BR BRPI0922057A patent/BRPI0922057A2/pt not_active Application Discontinuation
- 2009-11-19 HU HUE15151165A patent/HUE037938T2/hu unknown
- 2009-11-19 DK DK15151165.6T patent/DK2889033T3/en active
- 2009-11-19 NZ NZ593467A patent/NZ593467A/xx not_active IP Right Cessation
- 2009-11-19 MY MYPI2014003208A patent/MY173229A/en unknown
- 2009-11-19 PE PE2011001056A patent/PE20110711A1/es not_active Application Discontinuation
- 2009-11-19 ES ES15151165.6T patent/ES2673016T3/es active Active
- 2009-11-19 SI SI200930466T patent/SI2355822T1/sl unknown
- 2009-11-19 JP JP2011537621A patent/JP5272080B2/ja not_active Expired - Fee Related
- 2009-11-19 EP EP09756921A patent/EP2355822B1/en active Active
- 2009-11-19 MY MYPI2011002245A patent/MY159826A/en unknown
- 2009-11-19 HU HUE12185913A patent/HUE026815T2/en unknown
- 2009-11-19 DK DK12185913.6T patent/DK2540297T3/en active
- 2009-11-19 ES ES12185913.6T patent/ES2541528T3/es active Active
- 2009-11-19 TR TR2018/07944T patent/TR201807944T4/tr unknown
- 2009-11-19 CN CN201610020803.2A patent/CN105687190A/zh active Pending
- 2009-11-19 PT PT97569214T patent/PT2355822E/pt unknown
- 2009-11-19 PT PT121859136T patent/PT2540297E/pt unknown
- 2009-11-19 WO PCT/US2009/065173 patent/WO2010059844A1/en active Application Filing
- 2009-11-19 SI SI200931223T patent/SI2540297T1/sl unknown
- 2009-11-19 RU RU2011124515/15A patent/RU2532327C2/ru not_active IP Right Cessation
- 2009-11-19 CA CA3017886A patent/CA3017886A1/en not_active Abandoned
- 2009-11-19 CA CA2894860A patent/CA2894860C/en not_active Expired - Fee Related
-
2011
- 2011-05-16 IL IL212921A patent/IL212921A/en not_active IP Right Cessation
- 2011-05-19 CL CL2011001178A patent/CL2011001178A1/es unknown
- 2011-05-19 CO CO11061800A patent/CO6400190A2/es not_active Application Discontinuation
- 2011-05-20 CR CR20110267A patent/CR20110267A/es unknown
- 2011-05-23 EC EC2011011076A patent/ECSP11011076A/es unknown
- 2011-05-31 ZA ZA2011/04044A patent/ZA201104044B/en unknown
- 2011-11-30 HK HK11113010.6A patent/HK1158520A1/xx not_active IP Right Cessation
-
2012
- 2012-11-12 US US13/674,290 patent/US8569354B2/en not_active Expired - Fee Related
-
2013
- 2013-01-03 HR HRP20130007AT patent/HRP20130007T1/hr unknown
- 2013-01-07 CY CY20131100013T patent/CY1113671T1/el unknown
- 2013-01-09 SM SM201300003T patent/SMT201300003B/xx unknown
- 2013-04-17 JP JP2013086454A patent/JP5674854B2/ja not_active Expired - Fee Related
- 2013-12-23 US US14/139,178 patent/US20140148479A1/en not_active Abandoned
-
2014
- 2014-02-07 US US14/175,654 patent/US8815933B2/en not_active Expired - Fee Related
- 2014-06-04 RU RU2014122858A patent/RU2662560C2/ru not_active IP Right Cessation
- 2014-07-17 PH PH12014501629A patent/PH12014501629B1/en unknown
- 2014-10-08 US US14/509,305 patent/US20150265583A1/en not_active Abandoned
- 2014-11-26 JP JP2014238660A patent/JP5869653B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-01 HR HRP20150711TT patent/HRP20150711T1/hr unknown
- 2015-07-02 CY CY20151100575T patent/CY1116460T1/el unknown
- 2015-07-10 SM SM201500167T patent/SMT201500167B/xx unknown
- 2015-10-12 IL IL242035A patent/IL242035A0/en unknown
- 2015-10-12 IL IL242034A patent/IL242034A/en not_active IP Right Cessation
-
2016
- 2016-01-07 JP JP2016001812A patent/JP6223480B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-18 CL CL2017001853A patent/CL2017001853A1/es unknown
- 2017-10-03 JP JP2017193867A patent/JP2018039818A/ja active Pending
- 2017-10-27 US US15/796,475 patent/US20180271844A1/en not_active Abandoned
- 2017-12-06 IL IL256140A patent/IL256140A/en unknown
- 2017-12-14 IL IL256313A patent/IL256313A/en unknown
-
2018
- 2018-01-03 PH PH12018500023A patent/PH12018500023A1/en unknown
- 2018-05-25 CL CL2018001420A patent/CL2018001420A1/es unknown
- 2018-06-18 HR HRP20180942TT patent/HRP20180942T1/hr unknown
- 2018-06-20 CY CY20181100638T patent/CY1121607T1/el unknown
- 2018-07-11 RU RU2018125456A patent/RU2018125456A/ru unknown
-
2019
- 2019-11-22 JP JP2019210985A patent/JP2020040977A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1158520A1 (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3- yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
IL217768A0 (en) | Treatment of crohn's disease with laquinimod | |
AP3069A (en) | Thienopyridine derivatives for the treatment and prvention of dengue virus infection | |
IL207084A0 (en) | Bicyclic derivatives of azabicyclic carboxamides, preparation thereof and therapeutic use thereof | |
ZA201005201B (en) | Azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof | |
IL207078A0 (en) | Azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof | |
EP2509596A4 (en) | COMPOUNDS AND METHOD FOR THE TREATMENT OF EYE DISEASES | |
IL216967B (en) | The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases | |
NZ603625A (en) | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate | |
EP2431362A4 (en) | 3- (4-AMINOPHENYL) -2-FURANCARIC ACID DERIVATIVE AND PHARMACEUTICAL ACCEPTABLE SALT THEREOF | |
ZA200903653B (en) | Methods for treatment of cochlear and vestibular disorders | |
EP2421532A4 (en) | SPIPERON DERIVATIVES AND METHOD FOR THE TREATMENT OF ILLNESSES | |
ZA200900556B (en) | Use of flumazenil in the manufacture of a medicament for the treatment of depressive disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20191121 |